Table 2.

Cox regression analysis of death and reoperation

	Death		Reoperation
	Hazard Ratio (95% CI)	P-value	Hazard Ratio (95% CI)	P-value
Male gender	1.07 (0.92–1.24)	0.360	1.56 (0.91–2.66)	0.107
Age groupa
65–70	1.0		1.0
< 50	1.35 (0.55–3.33)	0.516	5.61 (1.59–19.8)	0.007*
50–65	1.05 (0.74–1.51)	0.77	2.44 (1.17–5.08)	0.017*
70–80	1.81 (1.43–2.28)	< 0.001*	0.71 (0.37–1.38)	0.312
≥ 80	3.19 (2.46–4.12)	< 0.001*	0.60 (0.21–1.70)	0.337
Reoperationb	1.06 (0.74–1.52)	0.747
Valve size
25	1.0		1.0
19–23	1.22 (1.03–1.45)	0.025*	0.73 (0.42–1.26)	0.252
27–29	0.94 (0.71–1.25)	0.658	1.03 (0.45–2.34)	0.948
Diabetes Mellitus	1.22 (0.99–1.51)	0.067*	1.38 (0.68–2.81)	0.369
Smoker	1.59 (1.29–1.97)	< 0.001*	1.61 (0.74–3.52)	0.234
Previous smoker	1.08 (0.91–1.28)	0.383	1.39 (0.77–2.51)	0.269
VP-PM	1.18 (0.95–1.48)	0.144	2.19 (1.21–3.98)	0.010*
EuroSCORE II < 4%	0.61 (0.43–0.87)	0.006*	0.12 (0.06–0.22)	< 0.001*
Hypertension treatment	1.01 (0.87–1.17)	0.889	0.98 (0.59–1.64)	0.945
Lipid-lowering treatmentc	0.68 (0.58–0.80)	< 0.001*	1.09 (0.61–1.96)	0.759

VP-PM Valve prosthesis-patient mismatch. *P < 0.05

^aAge groups for reoperation are sorted by the age of the primary CE-P procedure

^bReoperation after primary AVR with another CE-P or TAVR

^cCox regression of the first 10 years